TY - JOUR
T1 - Genome-wide association study in patients with pulmonary Mycobacterium avium complex disease
AU - Nontuberculous Mycobacteriosis and Bronchiectasis – Japan Research Consortium (NTM-JRC)
AU - Namkoong, Ho
AU - Omae, Yosuke
AU - Asakura, Takanori
AU - Ishii, Makoto
AU - Suzuki, Shoji
AU - Morimoto, Kozo
AU - Kawai, Yosuke
AU - Emoto, Katsura
AU - Oler, Andrew J.
AU - Szymanski, Eva P.
AU - Yoshida, Mitsunori
AU - Matsuda, Shuichi
AU - Yagi, Kazuma
AU - Hase, Isano
AU - Nishimura, Tomoyasu
AU - Sasaki, Yuka
AU - Asami, Takahiro
AU - Shiomi, Tetsuya
AU - Matsubara, Hiroaki
AU - Shimada, Hisato
AU - Hamamoto, Junko
AU - Jhun, Byung Woo
AU - Kim, Su Young
AU - Huh, Hee Jae
AU - Won, Hong Hee
AU - Ato, Manabu
AU - Kosaki, Kenjiro
AU - Betsuyaku, Tomoko
AU - Fukunaga, Koichi
AU - Kurashima, Atsuyuki
AU - Tettelin, Hervé
AU - Yanai, Hideki
AU - Mahasirimongkol, Surakameth
AU - Olivier, Kenneth N.
AU - Hoshino, Yoshihiko
AU - Koh, Won Jung
AU - Holland, Steven M.
AU - Tokunaga, Katsushi
AU - Hasegawa, Naoki
N1 - Funding Information:
Support statement: This work was supported by Japan Agency for Medical Research and Development (AMED) (project numbers JP17FK0108116H0401, JP17KM0405205H0002, JP18FK0108043, JP18FK0108075, 18km0405205h0003, 19km0405205h9904, 19kk0205012h0004, US–Japan Cooperative Medical Sciences Program Collaborative Awards 2019), Keio Gijuku Academic Development Funds, grant-in-aid for research activity start-up (JSPS KAKENHI) (grant number 15H06590), grant-in-aid for young scientists (B) (JSPS KAKENHI) (grant numbers 15K19039, 17K16066), grant-in-aid for scientific research (B) (grant numbers 19H03704, 15H05271, 24406010), and National Research Foundation of Korea (NRF) funded by the Korea government (MSIT) (grant number NRF-2018R1A2A1A05018309). This work was supported in part by federal funds to the Institute for Genome Sciences from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract number HHSN272200900009CJSPS. This work was supported by NIAID/CBER Intramural Tuberculosis Research Initiative and by the intramural programs of the National Institute of Allergy and Infectious Diseases and the National Heart, Lung, and Blood Institute, National Institutes of Health. Funding information for this article has been deposited with the Crossref Funder Registry.
Funding Information:
Conflict of interest: H. Namkoong reports grants from JSPS ( JSPS KAKENHI grant number 15H06590), AMED (2019 US-Japan Collaborative Proposal 28863) and NIAID/CBER Intramural Tuberculosis Research Initiative (FY19 Start-up support from CAN 8020315), during the conduct of the study. Y. Omae reports grants from JSPS KAKENHI (18K15041), during the conduct of the study. T. Asakura reports grants from JSPS, outside the submitted work.
Funding Information:
M. Ishii reports grants from JSPS KAKENHI (18H02821, 18K19566), outside the submitted work. S. Suzuki reports grants from JSPS, outside the submitted work. K. Morimoto reports grants from AMED (2019 US-Japan Collaborative Proposal 28863), during the conduct of the study; personal fees for consultancy from INSMED, outside the submitted work. Y. Kawai has nothing to disclose. K. Emoto has nothing to disclose. A.J. Oler has nothing to disclose. E.P. Szymanski has nothing to disclose. M. Yoshida reports grants from JSPS (grant-in-aid for young scientists (B), JSPS KAKENHI grant number 17K16066), during the conduct of the study. S. Matsuda has nothing to disclose. K. Yagi has nothing to disclose. I. Hase has nothing to disclose. T. Nishimura reports grants from JSPS KAKENHI (16K09942), outside the submitted work. Y. Sasaki reports grants from JSPS ( JSPS KAKENHI grant number 15H06590), during the conduct of the study. T. Asami has nothing to disclose. T. Shiomi has nothing to disclose. H. Matsubara has nothing to disclose. H. Shimada has nothing to disclose. J. Hamamoto reports grants from JSPS KAKENHI (19K08610), outside the submitted work. B.W. Jhun reports grants from AMED (2019 US-Japan Collaborative Proposal 28863), during the conduct of the study. S-Y. Kim has nothing to disclose. H.J. Huh has nothing to disclose. H-H. Won has nothing to disclose. M. Ato reports grants from Japan Agency for Medical Research and Development, during the conduct of the study. K. Kosaki reports grants from Japan Agency for Medical Research and Development (AMED), outside the submitted work. T. Betsuyaku reports grants from JSPS KAKENHI and Japan Agency for Medical Research and Development (AMED), outside the submitted work. K. Fukunaga reports grants from JSPS KAKENHI and Japan Agency for Medical Research and Development (AMED), outside the submitted work. A. Kurashima reports personal fees for consultancy from Insmed, during the conduct of the study. H. Tettelin reports grants from NIAID (contract number HHSN272200900009CJSPS), during the conduct of the study. H. Yanai has nothing to disclose. S. Mahasirimongkol has nothing to disclose. K.N. Olivier reports non-financial support from AIT Therapeutics, non-financial support from Insmed, outside the submitted work. Y. Hoshino reports grants from The Japan Agency for Medical Research and Development/Japan International Cooperation Agency (AMED), during the conduct of the study ( JP18fk0108043 and JP18fk0108075). W-J. Koh reports grants from National Research Foundation of Korea (grant number NRF-2018R1A2A1A05018309), during the conduct of the study. S.M. Holland has nothing to disclose. K. Tokunaga reports grants from Japan Agency for Medical Research and Development (grant-in-aid for research JP17km0405205h0002), during the conduct of the study. N. Hasegawa reports grants from Japan Agency for Medical Research and Development (AMED), during the conduct of the study; grants from JSPS KAKENHI, personal fees for consultancy from INSMED, outside the submitted work.
Publisher Copyright:
© ERS 2021.
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Rationale Nontuberculous mycobacteria (NTM) are environmental mycobacteria that can cause a chronic progressive lung disease. Although epidemiological data indicate potential genetic predisposition, its nature remains unclear. Objectives We aimed to identify host susceptibility loci for Mycobacterium avium complex (MAC), the most common NTM pathogen. Methods This genome-wide association study (GWAS) was conducted in Japanese patients with pulmonary MAC and healthy controls, followed by genotyping of candidate single-nucleotide polymorphisms (SNPs) in another Japanese cohort. For verification by Korean and European ancestry, we performed SNP genotyping. Results The GWAS discovery set included 475 pulmonary MAC cases and 417 controls. Both GWAS and replication analysis of 591 pulmonary MAC cases and 718 controls revealed the strongest association with chromosome 16p21, particularly with rs109592 (p=1.64×10−13, OR 0.54), which is in an intronic region of the calcineurin-like EF-hand protein 2 (CHP2). Expression quantitative trait loci analysis demonstrated an association with lung CHP2 expression. CHP2 was expressed in the lung tissue in pulmonary MAC disease. This SNP was associated with the nodular bronchiectasis subtype. Additionally, this SNP was significantly associated with the disease in patients of Korean (p=2.18×10−12, OR 0.54) and European (p=5.12×10−03, OR 0.63) ancestry. Conclusions We identified rs109592 in the CHP2 locus as a susceptibility marker for pulmonary MAC disease.
AB - Rationale Nontuberculous mycobacteria (NTM) are environmental mycobacteria that can cause a chronic progressive lung disease. Although epidemiological data indicate potential genetic predisposition, its nature remains unclear. Objectives We aimed to identify host susceptibility loci for Mycobacterium avium complex (MAC), the most common NTM pathogen. Methods This genome-wide association study (GWAS) was conducted in Japanese patients with pulmonary MAC and healthy controls, followed by genotyping of candidate single-nucleotide polymorphisms (SNPs) in another Japanese cohort. For verification by Korean and European ancestry, we performed SNP genotyping. Results The GWAS discovery set included 475 pulmonary MAC cases and 417 controls. Both GWAS and replication analysis of 591 pulmonary MAC cases and 718 controls revealed the strongest association with chromosome 16p21, particularly with rs109592 (p=1.64×10−13, OR 0.54), which is in an intronic region of the calcineurin-like EF-hand protein 2 (CHP2). Expression quantitative trait loci analysis demonstrated an association with lung CHP2 expression. CHP2 was expressed in the lung tissue in pulmonary MAC disease. This SNP was associated with the nodular bronchiectasis subtype. Additionally, this SNP was significantly associated with the disease in patients of Korean (p=2.18×10−12, OR 0.54) and European (p=5.12×10−03, OR 0.63) ancestry. Conclusions We identified rs109592 in the CHP2 locus as a susceptibility marker for pulmonary MAC disease.
UR - http://www.scopus.com/inward/record.url?scp=85113884063&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113884063&partnerID=8YFLogxK
U2 - 10.1183/13993003.02269-2019
DO - 10.1183/13993003.02269-2019
M3 - Article
C2 - 33542050
AN - SCOPUS:85113884063
SN - 0903-1936
VL - 58
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 2
M1 - 1902269
ER -